×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

North America Bedsores Pressure sores Market Trends

ID: MRFR/MED/0263-HCR
114 Pages
Kinjoll Dey
February 2026

North America Bedsores or Pressure Sores Market Research Report Information by Diagnosis (Blood Tests and Others), by Treatment Type (Medications, Device Types, and Others), and  by End-User (Hospitals and Clinics, Diagnostic Centers, and Others) – Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

North America Bedsores Pressure sores Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the North America Bedsores Pressure sores Market

The market for pressure sores or bedsores is influenced by several key factors that impact both supply and demand for products and services related to prevention and treatment. One significant market factor is the aging population worldwide. As the global demographic shifts towards an older age structure, the prevalence of bedsores increases due to the higher vulnerability of elderly individuals to immobility and reduced skin resilience. This demographic trend directly contributes to a rising demand for pressure sore prevention and management solutions.

Healthcare infrastructure and spending also play a crucial role in shaping the pressure sores market. Countries with well-developed healthcare systems tend to allocate resources for advanced medical technologies, education, and preventative measures. This includes the adoption of specialized mattresses, cushions, and other support surfaces that aim to minimize the risk of pressure sores. In contrast, regions with limited access to healthcare resources may face challenges in preventing and treating bedsores, impacting the overall market dynamics.

Technological advancements contribute significantly to the evolution of the pressure sores market. Innovations in materials, design, and monitoring technologies have led to the development of more effective preventive measures and treatment modalities. For instance, pressure-relieving mattresses, sensor-equipped devices, and telemedicine solutions are continuously being introduced to enhance patient care and reduce the incidence of pressure sores. The market is responsive to these technological developments, with consumers and healthcare providers alike seeking the latest and most effective solutions.

Regulatory frameworks and healthcare policies also influence the pressure sores market. Governments and regulatory bodies set standards for patient care and often mandate the use of specific preventative measures in healthcare facilities. Compliance with these regulations drives the adoption of pressure sore prevention products and contributes to market growth. Additionally, reimbursement policies for healthcare providers may incentivize the use of advanced pressure-relieving devices and treatments, further shaping the market landscape.

Awareness and education are crucial market factors in the context of pressure sores. Increased awareness among healthcare professionals, caregivers, and patients about the risk factors, prevention strategies, and available products contribute to early intervention and better outcomes. Educational campaigns by healthcare organizations and manufacturers help disseminate information about the importance of pressure sore prevention, thereby fostering a proactive approach to addressing the issue.

Economic factors, such as disposable income and healthcare spending capacity, influence the purchasing behavior of individuals and healthcare institutions. In regions with higher economic prosperity, there is often greater access to advanced pressure sore prevention products and treatments. Conversely, in economically disadvantaged areas, access to such resources may be limited, leading to a higher prevalence of pressure sores and a different market landscape.

Author
Kinjoll Dey
Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the North America bedsores pressure sores market?

<p>The market valuation was 9.31 USD Billion in 2024.</p>

What is the projected market size for the North America bedsores pressure sores market by 2035?

<p>The market is projected to reach 63.35 USD Billion by 2035.</p>

What is the expected CAGR for the North America bedsores pressure sores market during the forecast period 2025 - 2035?

<p>The expected CAGR is 19.04% during the forecast period 2025 - 2035.</p>

Which segments are included in the North America bedsores pressure sores market?

<p>The market segments include Hospital, Home Care, Long-term Care Facilities, and Rehabilitation Centers.</p>

What were the valuations for the Hospital segment in 2024?

<p>The Hospital segment was valued at 3.72 USD Billion in 2024.</p>

How does the valuation of Stage II pressure sores compare to other stages in 2024?

<p>Stage II pressure sores had a valuation of 2.79 USD Billion, which was the highest among all stages.</p>

What treatment methods are included in the North America bedsores pressure sores market?

<p>Treatment methods include Dressings, Topical Agents, Surgical Interventions, and Support Surfaces.</p>

What was the valuation of Support Surfaces in 2024?

<p>Support Surfaces were valued at 2.57 USD Billion in 2024.</p>

Which companies are considered key players in the North America bedsores pressure sores market?

<p>Key players include Hill-Rom Holdings Inc, Stryker Corporation, and Medtronic plc, among others.</p>

What is the projected growth trend for the Home Care segment by 2035?

<p>The Home Care segment is expected to grow from 2.79 USD Billion in 2024 to a significantly higher valuation by 2035.</p>

Market Summary

As per Market Research Future analysis, the North America commercial pharmaceutical-analytics market Size was estimated at 9.5 USD Billion in 2024. The North America commercial pharmaceutical-analytics market is projected to grow from 11.31 USD Billion in 2025 to 65.0 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 19% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The North America commercial pharmaceutical-analytics market is poised for substantial growth driven by technological advancements and regulatory support.

  • The integration of AI and machine learning is transforming data analysis processes in the pharmaceutical sector.
  • There is an increasing emphasis on real-world evidence to enhance decision-making and patient outcomes in the US and Canada.
  • Regulatory support is facilitating the adoption of advanced analytics, thereby streamlining compliance and operational efficiency.
  • Rising demand for personalized medicine and advancements in data management technologies are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 9.5 (USD Billion)
2035 Market Size 65.0 (USD Billion)
CAGR (2025 - 2035) 19.1%

Major Players

IQVIA (US), Cerner Corporation (US), Optum (US), McKesson Corporation (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Philips Healthcare (NL)

Market Trends

The commercial pharmaceutical-analytics market is currently experiencing notable growth in North America, driven by the increasing demand for data-driven decision-making in the pharmaceutical sector. Companies are increasingly leveraging advanced analytics to enhance drug development processes, optimize clinical trials, and improve patient outcomes. This trend is further supported by the integration of artificial intelligence and machine learning technologies, which appear to streamline data analysis and provide deeper insights into market dynamics. Regulatory bodies are also encouraging the adoption of analytics to ensure compliance and enhance safety measures, which may contribute to the market's expansion. Moreover, the rise of personalized medicine is influencing the commercial pharmaceutical-analytics market, as stakeholders seek to tailor treatments based on individual patient data. This shift necessitates sophisticated analytical tools capable of processing vast amounts of information, thereby fostering innovation within the industry. As pharmaceutical companies continue to invest in analytics capabilities, the market is likely to witness further advancements in predictive modeling and real-world evidence generation, which could reshape the landscape of drug development and patient care in North America.

Integration of AI and Machine Learning

The incorporation of artificial intelligence and machine learning technologies is transforming the commercial pharmaceutical-analytics market. These tools enable companies to analyze complex datasets more efficiently, leading to improved decision-making and faster drug development cycles. As organizations adopt these technologies, they may enhance their ability to predict market trends and patient responses.

Focus on Real-World Evidence

There is a growing emphasis on real-world evidence in the commercial pharmaceutical-analytics market. Stakeholders are increasingly utilizing data from actual patient experiences to inform drug development and regulatory submissions. This trend suggests a shift towards more patient-centered approaches, which could improve treatment efficacy and safety.

Regulatory Support for Analytics Adoption

Regulatory agencies in North America are actively promoting the use of analytics within the pharmaceutical sector. By encouraging the integration of data analytics into compliance and safety protocols, these bodies aim to enhance the overall quality of healthcare. This support may drive further investment in analytical capabilities among pharmaceutical companies.

North America Bedsores Pressure sores Market Market Drivers

Increased Investment in R&D

The surge in research and development (R&D) investments is a significant driver for the commercial pharmaceutical-analytics market. Pharmaceutical companies are allocating substantial budgets to R&D, with an average increase of 8% annually in North America. This investment is aimed at discovering new drugs and therapies, necessitating sophisticated analytics to interpret complex data sets. The commercial pharmaceutical-analytics market plays a crucial role in supporting these R&D efforts by providing tools that analyze clinical trial data and optimize drug development processes. As R&D spending continues to rise, the demand for analytics solutions is expected to follow suit.

Rising Demand for Personalized Medicine

The increasing emphasis on personalized medicine is a pivotal driver for the commercial pharmaceutical-analytics market. As healthcare shifts towards tailored treatments, pharmaceutical companies are leveraging analytics to understand patient data better. This trend is evidenced by a projected growth rate of 12% in the personalized medicine sector, which directly influences the demand for advanced analytics solutions. By utilizing data analytics, companies can identify patient-specific responses to therapies, thereby enhancing treatment efficacy. The commercial pharmaceutical-analytics market is thus positioned to benefit significantly from this shift, as analytics tools become essential for developing targeted therapies and improving patient outcomes.

Emergence of Value-Based Healthcare Models

The shift towards value-based healthcare models is reshaping the commercial pharmaceutical-analytics market. As healthcare providers focus on patient outcomes rather than service volume, there is a growing need for analytics to measure the effectiveness of treatments. This transition is supported by a projected increase of 15% in the adoption of value-based care models in North America. Consequently, pharmaceutical companies are investing in analytics to demonstrate the value of their products. The commercial pharmaceutical-analytics market is likely to benefit from this trend, as analytics tools become essential for evaluating treatment outcomes and justifying healthcare expenditures.

Growing Regulatory Compliance Requirements

The evolving landscape of regulatory compliance is a critical driver for the commercial pharmaceutical-analytics market. Regulatory bodies in North America are increasingly mandating the use of analytics to ensure drug safety and efficacy. Companies must comply with stringent regulations, which often require detailed data analysis and reporting. This trend is reflected in the fact that 70% of pharmaceutical companies report increased spending on compliance-related analytics. The commercial pharmaceutical-analytics market is thus positioned to thrive as organizations seek to enhance their compliance capabilities through advanced analytics solutions.

Advancements in Data Management Technologies

Technological advancements in data management are transforming the commercial pharmaceutical-analytics market. The rise of cloud computing and big data technologies enables pharmaceutical companies to process vast amounts of data efficiently. In North America, the market for cloud-based analytics solutions is expected to reach $5 billion by 2026, indicating a robust demand for innovative data management tools. These technologies facilitate real-time data analysis, allowing companies to make informed decisions quickly. Consequently, the commercial pharmaceutical-analytics market is likely to experience accelerated growth as organizations adopt these advanced data management solutions to enhance their analytical capabilities.

Market Segment Insights

By Application: Hospital (Largest) vs. Home Care (Fastest-Growing)

<p>In the North America bedsores pressure sores market, hospitals are currently the largest segment, holding a significant share due to the high prevalence of bedsores among hospitalized patients. Home care has emerged as a rapidly expanding sector, driven by the increasing preference for at-home treatment and rehabilitation. This growth reflects a shift towards personalized care and cost-effective solutions for managing bedsores outside institutional settings. Long-term care facilities and rehabilitation centers also play crucial roles, but they are growing at a slower pace comparatively.</p>

<p>Hospital (Dominant) vs. Home Care (Emerging)</p>

<p>Hospitals are the dominant force in the North America bedsores pressure sores market, primarily due to their ability to provide specialized care and immediate access to advanced treatment technologies. The infrastructure of hospitals supports comprehensive patient management, ensuring effective monitoring and intervention for bedsores. On the other hand, the home care segment is emerging rapidly, emphasizing the trend towards patient-centric approaches, where comfort and convenience play integral roles. Home care offers personalized solutions that cater to individual needs, making it an attractive option for patients seeking to manage their conditions in a familiar environment. This evolution highlights the need for innovative products and services in both segments to meet their respective demands.</p>

By Type of Pressure Sore: Stage II (Largest) vs. Stage IV (Fastest-Growing)

<p>In the North America bedsores pressure sores market, Stage II pressure sores hold the largest market share, owing to their prevalence among patients with limited mobility and the necessity for timely intervention. Stage I and Stage III sores also contribute significantly to market dynamics, but Stage II’s combination of risk factors and treatment requirements positions it as the most substantial segment in this category. As care protocols evolve and awareness of pressure sore prevention becomes more widespread, the growth rate for Stage IV sores is rapidly increasing. These deep tissue injuries necessitate advanced treatment options and long-term care, making them vital in discussions about patient management and health care strategies. The focus on improving outcomes for these severe cases drives market growth and innovation in treatment solutions.</p>

<p>Stage II (Dominant) vs. Stage IV (Emerging)</p>

<p>Stage II pressure sores are characterized by partial-thickness skin loss, which often leads to significant patient discomfort and requires prompt attention. This segment remains predominant due to the high incidence rates in healthcare facilities and the necessity for preventive measures. On the other hand, Stage IV pressure sores, which are full-thickness injuries involving extensive damage to both skin and underlying tissues, are an emerging segment. They reflect a critical area of focus for healthcare providers, as their treatment requires aggressive interventions and a multidisciplinary approach. The rising recognition of the complexities involved in managing Stage IV sores indicates growing investment in research and product development, which in turn enhances the overall market landscape.</p>

By Treatment Method: Dressings (Largest) vs. Topical Agents (Fastest-Growing)

<p>In the North America bedsores pressure sores market, the treatment methods segment reveals a clear preference among healthcare providers, with dressings emerging as the largest contributor due to their ease of application and effectiveness in wound management. Topical agents, on the other hand, are rapidly gaining traction, demonstrating a significant rise in adoption rates as practitioners seek more advanced solutions for patient care.</p>

<p>Dressings (Dominant) vs. Topical Agents (Emerging)</p>

<p>Dressings play a dominant role in the treatment of bedsores as they are essential for protecting wounds and supporting healing. Their diverse range includes hydrocolloids, foams, and alginates, offering flexibility for various wound conditions. Meanwhile, topical agents represent an emerging category, characterized by formulations that include antimicrobials, growth factors, and enzymes. As healthcare facilities continue to prioritize infection prevention and enhance wound healing, the usage of topical agents is expected to surge, driven by innovations in product formulation and increasing awareness among clinicians.</p>

By Components: Software (Largest) vs. Services (Fastest-Growing)

In the North America commercial pharmaceutical-analytics market, the segment values of software and services showcase a notable disparity in their market share distribution. Software holds the largest share, benefiting from increased adoption among pharmaceutical companies seeking to streamline their operations and enhance data analytics capabilities. In contrast, services are rapidly gaining traction, driven by the growing demand for customization and integration, which are vital for effective analytics usage. Growth trends in this segment are shaped significantly by technological advancements and the pressing need for regulatory compliance among pharmaceutical firms. While software solutions are being optimized for better user experience and functionality, the services sector is evolving, with providers focusing on innovative delivery methods and specialized offerings, making it the fastest-growing component within the market. This dynamic interaction between software and services underscores the importance of adaptability in the competitive landscape.

Software (Dominant) vs. Services (Emerging)

Software is recognized as the dominant force in the North America commercial pharmaceutical-analytics market, characterized by robust functionalities and ease of integration within existing infrastructures. It empowers pharmaceutical firms to manage vast amounts of data efficiently, providing insights that drive strategic decision-making. Meanwhile, services are emerging as a critical component, characterized by tailored support, implementation expertise, and ongoing training for users. This segment is increasingly sought after as companies recognize the value of leveraging external expertise to maximize the benefits of their analytics investments. As the market continues to evolve, the interplay between software and services reveals a trend toward comprehensive solutions that blend technology with specialized support to meet the unique needs of the pharmaceutical industry.

Get more detailed insights about North America Bedsores or Pressure Sores Market Research Report forecast to 2035

Regional Insights

US : Leading Market with Robust Growth

The US pharmaceutical-analytics market holds a commanding share of 8.1% in North America, driven by increasing healthcare expenditures and a growing emphasis on data-driven decision-making. Key growth drivers include advancements in technology, rising demand for personalized medicine, and supportive government initiatives aimed at enhancing healthcare outcomes. Regulatory policies, such as the 21st Century Cures Act, promote innovation and streamline drug approval processes, further fueling market expansion. Additionally, significant investments in healthcare infrastructure bolster the analytics landscape.

Canada : Strategic Developments in Healthcare Analytics

Canada's pharmaceutical-analytics market, valued at 1.4%, is on an upward trajectory, supported by increasing healthcare investments and a focus on improving patient outcomes. Key growth drivers include the integration of advanced analytics in healthcare systems and government initiatives aimed at enhancing data accessibility. The Canadian government has implemented policies to support digital health transformation, which is crucial for analytics adoption. The demand for real-time data analytics is rising, particularly in urban centers like Toronto and Vancouver, where healthcare innovation is prioritized.

Key Players and Competitive Insights

The commercial pharmaceutical-analytics market in North America is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for data-driven decision-making in healthcare. Key players such as IQVIA (US), Cerner Corporation (US), and Optum (US) are at the forefront, leveraging their extensive data repositories and analytics capabilities to enhance patient outcomes and streamline operations. These companies are strategically positioned to capitalize on the growing emphasis on personalized medicine and real-time analytics, which are reshaping the market's competitive dynamics.In terms of business tactics, companies are increasingly localizing their operations and optimizing supply chains to enhance efficiency and responsiveness. The market appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies like McKesson Corporation (US) and Roche Diagnostics (CH) is significant. Their operational focus on partnerships and technological integration is likely to drive further consolidation and innovation within the sector.

In October IQVIA (US) announced a strategic partnership with a leading telehealth provider to enhance its analytics capabilities in remote patient monitoring. This collaboration is expected to integrate advanced analytics into telehealth services, thereby improving patient engagement and outcomes. The strategic importance of this move lies in its potential to position IQVIA as a leader in the rapidly evolving telehealth landscape, where data analytics plays a crucial role in patient management.

In September Cerner Corporation (US) launched a new cloud-based analytics platform aimed at improving interoperability among healthcare systems. This initiative is significant as it addresses the ongoing challenges of data silos in healthcare, enabling providers to access comprehensive patient data seamlessly. By enhancing interoperability, Cerner is likely to strengthen its market position and foster greater collaboration among healthcare stakeholders.

In August Optum (US) expanded its analytics services through the acquisition of a data science firm specializing in artificial intelligence. This acquisition is pivotal as it enhances Optum's capabilities in predictive analytics, allowing for more accurate forecasting of patient needs and resource allocation. The integration of AI into their analytics framework could provide Optum with a competitive edge in delivering personalized healthcare solutions.

As of November the competitive trends in the commercial pharmaceutical-analytics market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized healthcare solutions. This shift underscores the importance of agility and adaptability in a rapidly changing market environment.

Key Companies in the North America Bedsores Pressure sores Market include

Industry Developments

Future Outlook

North America Bedsores Pressure sores Market Future Outlook

The commercial pharmaceutical-analytics market is projected to grow at a 19.1% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for data-driven insights.

New opportunities lie in:

  • Integration of AI-driven predictive analytics tools for drug development.
  • Expansion of real-time data analytics platforms for clinical trials.
  • Development of personalized medicine analytics solutions to enhance patient outcomes.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

Market Segmentation

North America Bedsores Pressure sores Market Type Outlook

  • Descriptive Analytics
  • Predictive Analytics
  • Prescriptive Analytics

North America Bedsores Pressure sores Market Components Outlook

  • Software
  • Services

North America Bedsores Pressure sores Market Deployment Outlook

  • On-Premise
  • Web-Based/Cloud-Based

North America Bedsores Pressure sores Market Application Outlook

  • R&D
  • Marketing & Sales
  • Supply Chain Optimization
  • Internal Reporting

Report Scope

MARKET SIZE 2024 9.5(USD Billion)
MARKET SIZE 2025 11.31(USD Billion)
MARKET SIZE 2035 65.0(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 19.1% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled IQVIA (US), Cerner Corporation (US), Optum (US), McKesson Corporation (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Philips Healthcare (NL)
Segments Covered Type, Application, Deployment, Components
Key Market Opportunities Integration of artificial intelligence in drug development enhances efficiency in the commercial pharmaceutical-analytics market.
Key Market Dynamics Rising demand for data-driven insights drives innovation in the commercial pharmaceutical-analytics market.
Countries Covered US, Canada

FAQs

What is the current valuation of the North America bedsores pressure sores market?

<p>The market valuation was 9.31 USD Billion in 2024.</p>

What is the projected market size for the North America bedsores pressure sores market by 2035?

<p>The market is projected to reach 63.35 USD Billion by 2035.</p>

What is the expected CAGR for the North America bedsores pressure sores market during the forecast period 2025 - 2035?

<p>The expected CAGR is 19.04% during the forecast period 2025 - 2035.</p>

Which segments are included in the North America bedsores pressure sores market?

<p>The market segments include Hospital, Home Care, Long-term Care Facilities, and Rehabilitation Centers.</p>

What were the valuations for the Hospital segment in 2024?

<p>The Hospital segment was valued at 3.72 USD Billion in 2024.</p>

How does the valuation of Stage II pressure sores compare to other stages in 2024?

<p>Stage II pressure sores had a valuation of 2.79 USD Billion, which was the highest among all stages.</p>

What treatment methods are included in the North America bedsores pressure sores market?

<p>Treatment methods include Dressings, Topical Agents, Surgical Interventions, and Support Surfaces.</p>

What was the valuation of Support Surfaces in 2024?

<p>Support Surfaces were valued at 2.57 USD Billion in 2024.</p>

Which companies are considered key players in the North America bedsores pressure sores market?

<p>Key players include Hill-Rom Holdings Inc, Stryker Corporation, and Medtronic plc, among others.</p>

What is the projected growth trend for the Home Care segment by 2035?

<p>The Home Care segment is expected to grow from 2.79 USD Billion in 2024 to a significantly higher valuation by 2035.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Billion)
    2. | | 4.1.1 Hospital
    3. | | 4.1.2 Home Care
    4. | | 4.1.3 Long-term Care Facilities
    5. | | 4.1.4 Rehabilitation Centers
    6. | 4.2 Healthcare, BY Type of Pressure Sore (USD Billion)
    7. | | 4.2.1 Stage I
    8. | | 4.2.2 Stage II
    9. | | 4.2.3 Stage III
    10. | | 4.2.4 Stage IV
    11. | 4.3 Healthcare, BY Treatment Method (USD Billion)
    12. | | 4.3.1 Dressings
    13. | | 4.3.2 Topical Agents
    14. | | 4.3.3 Surgical Interventions
    15. | | 4.3.4 Support Surfaces
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Hill-Rom Holdings Inc (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Stryker Corporation (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Arjo (SE)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Medtronic plc (IE)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 3M Company (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Invacare Corporation (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 KCI Medical (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Smith & Nephew plc (GB)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Medi USA (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS BY APPLICATION
    3. | 6.3 NORTH AMERICA MARKET ANALYSIS BY TYPE OF PRESSURE SORE
    4. | 6.4 NORTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD
    5. | 6.5 KEY BUYING CRITERIA OF HEALTHCARE
    6. | 6.6 RESEARCH PROCESS OF MRFR
    7. | 6.7 DRO ANALYSIS OF HEALTHCARE
    8. | 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    9. | 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    10. | 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
    11. | 6.11 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    12. | 6.12 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    13. | 6.13 HEALTHCARE, BY TYPE OF PRESSURE SORE, 2024 (% SHARE)
    14. | 6.14 HEALTHCARE, BY TYPE OF PRESSURE SORE, 2024 TO 2035 (USD Billion)
    15. | 6.15 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
    16. | 6.16 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
    17. | 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
    5. | | 7.2.2 BY TYPE OF PRESSURE SORE, 2026-2035 (USD Billion)
    6. | | 7.2.3 BY TREATMENT METHOD, 2026-2035 (USD Billion)
    7. | 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    8. | | 7.3.1
    9. | 7.4 ACQUISITION/PARTNERSHIP
    10. | | 7.4.1

North America Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2022-2035)

  • Hospital
  • Home Care
  • Long-term Care Facilities
  • Rehabilitation Centers

Healthcare By Type of Pressure Sore (USD Billion, 2022-2035)

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Healthcare By Treatment Method (USD Billion, 2022-2035)

  • Dressings
  • Topical Agents
  • Surgical Interventions
  • Support Surfaces
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓